Please login to the form below
Tradjenta
This page shows the latest Tradjenta news and features for those working in and with pharma, biotech and healthcare.
Boehringer bolsters NASH pipeline with $870m Yuhan deal
Boehringer already has an existing relationship with Yuhan, which acts as the South Korean marketer for three of the German firm’s Eli Lilly-partnered diabetes therapies, Tradjenta (linagliptin), Trajenta Duo
Latest news
-
Lilly claims cluster headache first for CGRP drug Emgality
Tradjenta (linagliptin) and metformin – and said yesterday the FDA had started its review of the Boehringer Ingelheim-partnered drug.
-
FDA clears Jardiance combo for type 2 diabetes
In March they secured FDA approval for Glyxambi, which places empagliflozin alongside the active ingredient in their DPP-4 inhibitor product Tradjenta (linagliptin), ahead of competition from AZ and
-
Lilly/Boehringer's diabetes combination Glyxambi debuts in US
Interestingly, Glyxambi has been priced at around a 24% discount to the combined cost of parent products Tradjenta (linagliptin) and Jardiance (empagliflozin), in recognition of the need to encourage switching from
-
MSD launches diabetes programme with pharmacy network
More recent rivals include Lilly and Boehringer Ingelheim's Tradjenta/Trajenta (linagliptin) and AstraZeneca's Onglyza (saxagliptin).
-
J&J's combo diabetes drug held up by FDA
That rate suggests faster take-up in the early weeks than either AZ/BMS Onglyza (saxagliptin) or Boehringer/Lilly's Tradjenta (linagliptin), two diabetes treatments in the DPP-4 inhibitor class.
More from news
Approximately 1 fully matching, plus 13 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- 2023 PM Society Awards – winners announced
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- GSK reports positive phase 3 results for five-in-one meningococcal vaccine candidate
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
PMHub
Havas Life Medicom
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
